A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 288-297

  Zuo, Shan Ru ^a   Zuo, Xiao Cong ^a   Wang, Chun Jiang ^a   Ma, Yu Tao ^a   Zhang, Hao Ye ^a   Li, Zuo Jun ^a   Song, Li Ying ^a   Deng, Zhen Zhen ^a   Liu, Shi Kun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

chronic hepatitis B; entecavir; meta analysis; tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; CASE CONTROL STUDY; CHRONIC HEPATITIS B; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DNA REPLICATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; MYALGIA; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; VOMITING; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B, CHRONIC; ODDS RATIO; PATIENT SELECTION; RISK FACTOR; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; ODDS RATIO; PATIENT SELECTION; RISK FACTORS; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84960454664     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.409     Document Type: Article

References (40)

1. Pol S, Lampertico P,. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012; 19 (6): 377-386.
2. Liu Y, Wang C, Zhong Y, et al., Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat. 2011; 18 (4): e29-e39.
3. Gordon SC, Krastev Z, Horban A, et al., Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013; 58 (2): 505-513.
4. Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK,. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res. 2013; 100 (2): 300-305.
5. Liaw YF, Leung N, Kao JH, et al., Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2 (3): 263-283.
6. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology. 2009; 50 (3): 661-662.
7. EASL clinical practice guidelines. Management of chronic hepatitis B. Gastroenterol Clin Biol. 2009; 33 (6-7): 539-554.
8. Zhang Y, Wu Y, Ye S, et al., The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo. Virus Res. 2013; 171 (1): 65-70.
9. Liaw YF,. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B [Abstract]. Antivir Chem Chemother. 2001; 12 (suppl 1): 67-71.
10. Liaw YF, Gane E, Leung N, et al., 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136 (2): 486-495.
11. Ozaras R, Mete B, Ceylan B, et al., First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. Eur J Gastroenterol Hepatol. 2014; 26 (7): 774-780.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131 (6): 1743-1751.
13. Melissa O,. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011; 4: 55-64.
14. Hou JL, Sun J,. Influence of nucleoside analogues resistance on anti-HBV treatment. Zhonghua Yi Xue Za Zhi. 2005; 85 (17): 1156-1157.
15. You JH, Chan FW,. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opin Pharmacother. 2008; 9 (15): 2673-2681.
16. Marcellin P, Heathcote EJ, Buti M, et al., Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359 (23): 2442-2455.
17. Lavocat F, Deny P, Pichoud C, et al., Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013; 59 (4): 684-695.
18. Snow-Lampart A, Chappell B, Curtis M, et al., No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011; 53 (3): 763-773.
19. Gao L, Trinh HN, Li J, Nguyen MH,. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther. 2014; 39 (6): 629-637.
20. Woo G, Tomlinson G, Nishikawa Y, et al., Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010; 139 (4): 1218-1229.
21. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57 (1): 167-185.
22. Ridruejo E,. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol. 2014; 20 (23): 7169-7180.
23. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS,. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol. 2012; 23 (3): 247-252.
24. Guzelbulut F, Ovunc AO, Oetinkaya ZA, et al., Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology. 2012; 59 (114): 477-480.
25. Köklü S, Tuna Y, Gulsen MT, et al., Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013; 11 (1): 88-94.
26. Ceylan B, Yardimci C, Fincanci M, et al., Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci. 2013; 17 (18): 2467-2473.
27. Higgins JP, Altman DG, Gotzsche PC, et al., Cochrane Statistical Methods Group: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
28. Egger M, Davey SG, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315 (7109): 629-634.
29. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50 (4): 1088-1101.
30. Liaw YF, Sheen IS, Lee CM, et al., Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53 (1): 62-72.
31. Sriprayoon T, Lueangarum S, Suwanwela C,. Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Gastroenterology. 2012; 142: S695.
32. Jayakumar R, Joshi YK, Singh S,. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians. 2012; 4 (1): 10-16.
33. Carey I, Nguyen HL, Joe D, et al., De-novo antiviral therapy with nucleos(t)ide analogues in "real-life" patients with chronic hepatitis B infection: comparison of virological responses between lamivudine adefovir, entecavir vs. tenofovir therapy [Abstract]. Hepatology. 2011; 54 (suppl): 1396.
34. Lin B, Ha NB, Liu A, et al., Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013; 28 (5): 855-860.
35. Ke W, Liu L, Zhang C, et al., Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014; 9 (6): e98865.
36. Wiens A, Lenzi L, Venson R, et al., Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013; 33 (2): 144-151.
37. Liu F, Wang X, Wei F, et al., Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014; 11: 59.
38. He Z, Wang J, Liu K, et al., Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin Res Hepatol Gastroenterol. 2012; 36 (6): 592-597.
39. Petersen J, Heyne R, Mauss S, et al., Effectiveness of tenofovir for chronic hepatitis B in field practice-2 year interim results from the prospective German multicenter non-interventional study (GEMINIS) [Abstract]. J Hepatol. 2013; 58 (suppl): 768.
40. Gill U, Al-Shamma S, Burke KB, et al., Bone mineral density loss in tenofovir treated chronic hepatitis B virus (HBV) patients is a consequence of vitamin D deficiency and not tenofovir therapy[Abstract]. Hepatology. 2011; 54 (suppl): 1376.